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Abstract 
Background: Microdialysis is a well‑established technology that can be used for continuous blood glucose moni‑
toring. We determined point and trend accuracy, and reliability of a microdialysis‑based continuous blood glucose‑
monitoring device (EIRUS®) in critically ill patients.
Methods: Prospective study involving patients with an expected intensive care unit stay of ≥48 h. Every 15 min, 
device readings were compared with blood glucose values measured in arterial blood during blocks of 8 h per day for 
a maximum of 3 days. The Clarke error grid, Bland–Altman plot, mean absolute relative difference and glucose predic‑
tion error analysis were used to express point accuracy and the rate error grid to express trend accuracy. Reliability 
testing included aspects of the device and the external sensor, and the special central venous catheter (CVC) with a 
semipermeable membrane for use with this device.
Results: We collected 594 paired values in 12 patients (65 [26–80; 8–97] (median [IQR; total range]) paired values 
per patient). Point accuracy: 93.6 % of paired values were in zone A of the Clarke error grid, 6.4 % were in zone B; bias 
was 4.1 mg/dL with an upper limit of agreement of 28.6 mg/dL and a lower level of agreement of −20.5 mg/dL in 
the Bland–Altman analysis; 93.6 % of the values ≥75 mg/dL were within 20 % of the reference values in the glucose 
prediction error analysis; the mean absolute relative difference was 7.5 %. Trend accuracy: 96.4 % of the paired values 
were in zone A, and 3.3 and 0.3 % were in zone B and zone C of the rate error grid. Reliability: out of 16 sensors, 4 had 
to be replaced prematurely; out of 12 CVCs, two malfunctioned (one after unintentional flushing by unsupervised 
nurses of the ports connected to the internal microdialysis chamber, causing rupture of the semipermeable mem‑
brane; one for an unknown reason). Device start‑up time was 58 [56–67] min; availability of real‑time data was 100 % 
of the connection time.
Conclusions: In this study in critically ill patients who had no hypoglycemic episodes and a limited number of hyper‑
glycemic excursions, point accuracy of the device was moderate to good. Trend accuracy was very good. The device 
had no downtimes, but 4 out of 16 external sensors and 2 out of 12 CVCs had practical problems.
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Background
Most if not all critically ill patients receive intravenous 
infusion of insulin for blood glucose control at some 
point during stay in the intensive care unit (ICU) [1]. This 
strategy requires frequent blood glucose measurements 
for the guidance of insulin titrations, but this is both 
time- and blood-consuming [2]. Automation of blood 
sampling and glucose measurement through continuous 
glucose monitor (CGM) devices could reduce this burden 
and has the potential to improve overall blood glucose 
control [3, 4].
Microdialysis offers the opportunity to sample blood 
analytes with high accuracy but without the need for 
drawing blood samples. EIRUS® (Maquet Critical Care 
AB, Solna, Sweden), a microdialysis-based device that 
can measure blood glucose and lactate levels, has been 
tested and validated previously in studies in surgical 
patients, where it has been found to be safe and accurate 
[4–7]. To date, its accuracy with regard to blood glu-
cose monitoring, and reliability have not yet been tested 
extensively in ICU patients [4, 6].
We hypothesized the EIRUS® system to be point and 
trend accurate and to be reliable in ICU patients. To test 
this hypothesis, we used this CGM device in a series of 
critically ill patients, to compare device readings with 
frequently measured arterial blood glucose values. Along 
the study, we determined reliability of the device and the 
special central venous catheter (CVC) with a semiperme-
able membrane designed for use with this device.
Methods
Study design and population
This investigator-initiated prospective study was con-
ducted in the mixed medical-surgical ICU of the Aca-
demic Medical Center, Amsterdam, The Netherlands. 
The Institutional Review Board of the Academic Medical 
Center approved the study protocol, and informed con-
sent was obtained from all patients or their legal repre-
sentatives before start of the study. Maquet Critical Care 
AB provided the CGM device and its disposables free of 
charge. Maquet Critical Care AB had influence neither 
on the design of this study nor on reporting of the results. 
The study was registered at the Netherlands Trial Regis-
ter (NTR4527).
Patients were eligible for participation if they were at 
least 18  years old, were expected to stay in the ICU for 
≥48 h, had an arterial catheter in place and were in need 
of a (new) CVC. Patients were excluded if they partici-
pated in another investigational drug or device study or 
were known to be pregnant.
Blood glucose control
ICU nurses followed a local guideline aiming at a blood 
glucose level between 90 and 144  mg/dL (5–8  mmol/L) 
as part of standard care. This guideline mandated nurses 
to measure blood glucose every 4 h, or more frequently 
when glucose levels were out of range or when rapid 
changes were expected. Infusion of insulin was started 
when glucose levels were over 144  mg/dL and stopped 
when glucose was lower than 61  mg/dL. Adjustments 
of insulin titration were based on sliding scales. More 
details can be found in Additional file  1. In addition, 
details on how nurses were trained can also be found in 
Additional file 1.
During the study, ICU nurses were not allowed to 
change insulin infusion rate based on the readings by the 
device. The ICU nurses, however, had access to device 
readings and additional arterial blood glucose measure-
ments were allowed if the device suggested rapid changes 
in the glucose level or when there was a trend toward 
hypoglycemia. In addition, the ICU nurses could also 
adjust insulin infusion rates based on reference blood 
glucose values obtained during study observation periods 
(see below).
The study device
For intravenous microdialysis-based glucose monitor-
ing, a special CVC with a semipermeable membrane 
(Maquet Critical Care AB, Solna, Sweden) is needed. 
This CVC has five lumens, three ‘normal’ ports for 
intravenous administration of fluids or medication 
and two ‘special’ ports for transport of normal saline 
alongside the semipermeable membrane, which should 
not be flushed and cannot be used for intravenous 
administration of fluids or medication. The ‘afferent’ 
port is connected to a saline-filled syringe placed in 
the syringe pump of the device. The ‘efferent’ port is 
connected to the disposable sensor. Small metabolites 
such as glucose pass through the semipermeable mem-
brane creating equilibrium between blood and the 
dialysate. The dialysate is pumped over the sensor in a 
continuous fashion, where the glucose oxidase method 
is used to measure the glucose level [4, 5]. The device 
can be used for a maximum of 96 h per sensor. Refer-
ence measurements are needed for calibration of the 
device, which is performed at start-up and every 8  h 
thereafter.
Of note, because the dialysate needs to be transported 
to the sensor outside the patient, where measurements 
are performed, there is a delay in time of 5 min between 
dialysate formation and the actual measurements.
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Study procedures
In three blocks of 8  h per day, and for a maximum of 
3 days, every 15 min an arterial blood sample of 200 µL 
was drawn through an existing arterial line. Blood glu-
cose levels were measured using a blood gas analyzer 
(RAPIDLab 1265, Siemens Healthcare Diagnostics, The 
Hague, The Netherlands).
Definitions of the metrics used to assess device reliabil-
ity, including those suggested by recent consensus rec-
ommendations [8], are described in detail in Additional 
file 1 and included the percentage of real-time data, skips 
in data acquisition, failures to calibrate, sensor failures 
and CVC failures.
Power calculation
Based on previous studies [9, 10], we chose to collect 
approximately 1000 paired measurements or to connect 
the device to a minimum number of 11 patients. Inclu-
sion of patients was restricted by the time the device was 
available for this study and the number of disposable 
CVCs and sensors provided by the manufacturer.
Analysis plan
Patient characteristics were reported as means, medians 
or percentages, where appropriate. Because of the delay 
between dialysate formation and the actual measure-
ments of the blood glucose level, we subtracted 5  min 
from the time stamp of the values of the CGM device; 
as such reference blood glucose values matched with 
the moment dialysate was formed. Subsequently, device 
and reference measurements were merged. Paired meas-
urements were used for determining point and trend 
accuracy of the device. To be considered for the statisti-
cal analysis, each patient needed to have at least multi-
ple samples with at most 30  min in between. However, 
patients excluded for statistical analysis remained 
included in the reliability analysis. While each paired 
sample was included in the point accuracy analysis, only 
the samples with a gap of at most 30 min to the next sam-
ple were included in the trend accuracy analysis. In addi-
tion, when the device was calibrated within the daily 8-h 
block of intense sampling, the calibration sample and the 
subsequent sample were not considered for trend accu-
racy analysis. This way, large changes in trend due to the 
calibration were excluded from the analysis.
Point accuracy was expressed using a Clarke error grid, 
a Bland–Altman plot, the glucose prediction error analy-
sis and the mean absolute relative difference (MARD). To 
be considered point accurate, at least 95 % of values must 
be in zone A, a maximum of 5 % can be in zone B, and 
no values are allowed in zones C to E of the Clarke error 
grid [11]. Also, the MARD should be below 14 %; a value 
above 18 % represent poor accuracy [3].
Trend accuracy was expressed using rate error grid 
analysis (R-EGA) [12]. Values outside zones A and B of 
the R-EGA corresponding to values in zones A and B 
of the Clarke error grid were considered benign errors. 
On the other hand, values outside zones A and B of the 
R-EGA corresponding to values outside zones A and B of 
the Clarke error grid were considered erroneous readings 
[12].
Post hoc analysis
Point accuracy was also expressed using the recently 
published surveillance error grid [13].
Two of the CVCs were malfunctioning. In one case, it 
was immediately clear that the CVC was defect, and no 
additional measurements were performed. In another 
case, this was not immediately clear, and only after 
reviewing the readings it became clear that the CVC 
started to malfunction from a certain time point. We 
chose to perform a post hoc analysis excluding the data 
from that patient.
Results
A total of 12 patients were included in whom 598 paired 
measurements were available. Figure 1 shows the CON-
SORT diagram. One patient was excluded from the point 
and trend accuracy analyses because no comparative 
samples could be obtained while the device was con-
nected due to calibration problems. In one patient, four 
arterial blood samples had to be discarded as they were 
diluted during sampling. Thus, we had 594 samples (65 
[26–80; 8–97] (median [IQR; total range]) paired values 
per patient) for determining point accuracy of the CGM 
device. For trend accuracy analysis, 482 samples were 
used. Patient characteristics are shown in Table 1. Met-
rics of glucose control are shown in Table 2.
Point and trend accuracy
The Clarke error grid, Bland–Altman plot and glucose 
prediction error grid are presented in Fig. 2. Bias in the 
Bland–Altman plot was 4.1  mg/dL with an upper limit 
of agreement of 28.6  mg/dL and a lower limit of agree-
ment of −20.5  mg/dL. Glucose prediction error analy-
sis showed that 93.6  % of the values ≥75  mg/dL within 
twenty percent of the values measured by the blood gas 
analyzer were within range. The MARD was 7.5  %. The 
rate error grid is presented in Fig. 3, consisting of 99.7 % 
accurate readings and 0.3 % benign errors.
Reliability
Table  3 shows reliability results. Start-up time was 58 
[56–67; 48–112.8] (median [IQR; total range])  min. In 
three patients, the initial sensor could not be calibrated 
at start-up, and a second sensor was needed. In two 
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patients, the CVC malfunctioned after some hours. In 
one patient, this was due to improper handling by one of 
the trained ICU nurses. This and other details on reliabil-
ity are discussed in more detail in Additional file 1.
Post hoc analysis
The surveillance error grid is presented in Additional 
file 1: Figure S1.
Results of the post hoc analysis excluding the data 
from the patient mentioned above in whom the CVC 
was malfunctioning for unknown reasons is presented 
in Additional file 1: Figure S2, Figure S3, Figure S4 and 
Figure S5.
Discussion
In this study in a cohort of critically ill patients, point 
accuracy of a microdialysis-based CGM device devel-
oped was moderate to good. Trend accuracy was very 
good. Reliability was moderate, seen as 4 out of 16 exter-
nal sensors could not be used and 2 out of 12 CVCs had 
practical problems.
Point accuracy in the present study was less than the 
point accuracy reported from two previous studies in 
patients after cardiac surgery [4, 6]. In these studies, all 
paired values were in zones A and B, with 97 and 99 % of 
values in zone A of the Clark error grid, and the MARD 
was only 5.6 and 5 %, respectively. Both those studies and 
the present study used arterial blood gas analyzers as a 
reference standard. The present study, however, was con-
ducted in patients that were more severely ill than car-
diac surgery patients, reflected by a longer length of stay 
in the ICU stay (15 vs. 3 days) and hospital (20 vs. 8 days). 
Thus, these two studies included completely different 
patients, which could at least in part explain the differ-
ences. The results of the present study, however, are very 
similar to a pilot study in abdominal surgery patients [5], 
in which all paired values were in zones A and B, with 
94 % of values in zone A of the Clark error grid.
According to a recent consensus on blood glucose 
monitoring, 95 % of paired values need to be in zone A 
of the Clarke error grid to qualify a device as point accu-
rate [11]. In contrast, a more recent consensus among a 
panel of ICU experts, the MARD should be <14  % [3]. 
While the studied device did not meet the first criteria, 
it did meet the last. There are no generally accepted crite-
ria for trend accuracy of CGM devices in the ICU setting 
[3]. Nonetheless, we believe EIRUS to be very accurate, 
as only one value was in the benign error range [12]. In 
addition, it should be noted that the paired measurement 
in zone C mentioned above came from the patient in 
Fig. 1 Consolidated standards of reporting trials (CONSORT) diagram
Table 1 Patient characteristics
IQR interquartile range, BMI body mass index, APACHE II acute physiology and 
chronic health evaluation II, SAPS II sepsis-related organ failure assessment score 
II, ICU intensive care unit, LOS length of stay
Age in years, median [IQR]) 65 [60–79]
Male gender, number (%) 6/50 %
Race, number (%)
 Caucasian 10 (83.3 %)
 Black 1 (8.3 %)
 Asian 1 (8.3 %)
BMI in kg/m2, median [IQR] 23 [20–27] 
Admission type, number (%)
 Medical 6 (50 %)
 Emergency surgery 3 (25 %)
 Planned surgery 3 (25 %)
History of diabetes, number (%)
 No diabetes 11 (92 %)
 Diabetes, unknown treatment 1 (8 %)
 Diabetes treated with insulin 0 (0 %)
 Diabetes treated with oral agents 0 (0 %)
APACHE II, median [IQR] 21 [18–26]
SAPS II, median [IQR] 44 [37–53]
ICU LOS, days, median [IQR] 15 [7–17]
Hospital LOS, days, median [IQR] 20 [18–35]
ICU mortality, number (%) 7 (58 %)
Hospital mortality, number (%) 8 (67 %)
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whom the special CVC was malfunctioning. Since both 
glucose and lactate measured by the device decreased 
rapidly and non-physiologically, we suspect that the sem-
ipermeable membrane of that CVC broke.
Both the afferent and efferent ports of the CVC, con-
nected to the dialysate chamber, were labeled with tags 
mentioning not to flush these ports. Unfortunately, 
unsupervised nurses thought there was backflow of 
blood in the afferent port because of the deep-red/pur-
ple color and flushed it with normal saline immediately. 
This resulted in a rupture of the delicate semipermeable 
membrane and thus malfunctioning of the CVC: Saline 
pumped into the chamber disappeared into the circula-
tion, and the efferent port stopped producing dialysate. 
After this we continued using the special CVC as a 
normal CVC, with two stops at the extra ports. The 
manufacturer changed the color of the lumen and its 
connector to prevent this incident after this study. These 
problems, however, did raise some concerns. However, 
we do not believe that these problems were caused by an 
insufficient introduction of the study device in the unit 
since we organized multiple training sessions for nurses 
Table 2 Metrics of glucose control
IQR interquartile range
Total number of measurements 594
Mean blood glucose level per patient, mg/dL, median [IQR; total range] 133 [118–140; 112–162]
Standard deviation of blood glucose level per patient, mg/dL, median [IQR; total range] 15 [11–18; 1–49]
Number of measurements per patient, median, [IQR; total range] 65 [26–80; 8–97]
Mild hyperglycemia 150–179 mg/dL in measurements, number (%) 62 (10)
Mild hyperglycemia 150–179 mg/dL in patients, number (%) 10 (91)
Severe hyperglycemia >180 mg/dL in measurements, number (%) 29 (5)
Severe hyperglycemia >180 mg/dL in patients, number (%) 3 (27)
Severe hypoglycemia ≤40 mg/dL in measurements, number (%) 0
Severe hypoglycemia ≤40 mg/dL in patients, number (%) 0
Mild hypoglycemia 41–70 mg/dL in measurements, number (%) 0
Mild hypoglycemia 41–70 mg/dL in patients, number (%) 0
Fig. 2 Measures of point accuracy. Bland–Altman plot (upper left panel), glucose prediction error grid (lower left panel) and Clarke error grid (right 
panel)
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and instructed nurses individually when a patient was 
included in the study and monitored by the device.
Our study has several limitations. First and most 
importantly, no hypoglycemic periods were captured 
during the study, and the number of hyperglycemic 
events was small. While the device proved point accu-
rate in the hypoglycemic range in one study in animals 
[14], we remain uncertain on hypoglycemic performance 
in ICU patients. The absence of hypoglycemia might be 
explained by the fact that reference measurements were 
performed very frequently and because nurses had access 
to the device readings. Nurses were allowed to use the 
reference measurements and thus could improve blood 
glucose control (i.e., prevent hypoglycemic events). Even 
the device readings could have helped nurses to prevent 
dangerous excursions of the blood glucose level, even 
though they knew that this was an investigational device. 
The local Institutional Review Board did not accept 
blinding the nurses for the reference measurements and 
the device readings. In addition, the fact that we only 
actively collected paired measurements during daytime 
hours means that we might have missed possible inter-
esting data overnight. More paired samples, also outside 
working hours, could have yielded more hypoglycemic 
events. To make a more conclusive statement on device 
accuracy in the hypoglycemic range, other methods for 
capturing hypoglycemic and hyperglycemic events have 
to be further explored. One recently suggested way to 
improve the execution of accuracy testing of investiga-
tional devices in the clinical setting includes data mining 
of electronic medical records [15, 16]. Data mining is a 
technique that uses large quantities of data in search for 
certain events, in this case hypoglycemia and hypergly-
cemia. Comparison between consecutive measurements 
of the blood glucose level by means of a CGM device 
and comparative measurements in a central laboratory 
then could be used to determine the accuracy in these 
extreme situations. This approach certainly increases the 
number of hypoglycemic and hyperglycemic events that 
can be used for accuracy testing, but of course requires 
extensive use in one of more intensive care units. Finally, 
as of September of 2015, shortly after analyzing the data 
before reaching our goal of 1000 paired samples, we had 
to stop the study prematurely. The data allowed for a suf-
ficiently narrow interval of confidence on the point and 
trend accuracy of the machine and therefore we did not 
consider it ethically justified to include more patients, 
seen the potential burden and risks of obtaining blood 
samples every 15 min.
There were also several strengths to this study. This is 
the first study to date to investigate trend accuracy of a 
CGM device in critically ill patients. In addition, the 
investigated microdialysis CGM device had not been 
tested in a mixed ICU before. This makes the results of 
this study more clinically applicable as this is indeed the 
patient population in which glucose monitoring is most 
relevant. Finally, we used precise blood gas analyzers for 
reference measurements, and we corrected for the 5-min 
Fig. 3 Rate error grid of the continuous glucose error grid analysis. 
This grid is divided into similar zones as the Clarke error grid. Perfectly 
trend accurate values are the dashed line in the middle
Table 3 Reliability and safety of the CGM device
IQR, interquartile range; initialization time, total time from connecting the 
device, to being ready for calibration; total start-up time, total time from 
connecting the device, to displaying the first glucose value
In total
Total number of sensors used 16
Per patient
Number of sensors used, median [IQR; total range] 1.0 [1.0–2.0; 1–2]
Total connection time, median [IQR; total range] 50.8 [13.5–54.7; 
2.5–55.8] h
Real‑time data, median [IQR; total range] (%) 50.8 [13.5–54.7; 
2.5–55.8] h 
(100 %)
Time of skips in data acquisition 0.0 h
Percentage of time skips in data acquisition 0.0 h
Initialization time, median [IQR; total range] 42 [42–43; 
40.8–62.4] min
Total start‑up time, median [IQR; total range] 58 [56–67; 
48–112.8] min
Number of calibrations needed before start,  
median [IQR; total range]
1.0 [1.0–1.3; 1–3]
Number of calibrations during duration  
of measurement, median [IQR; total range]
6.5 [2.0–7.0; 1–8]
Number of failed calibrations during duration  
of measurement, median [IQR; total range]
0.5 [0.0–2.0; 0–3]
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delay between formation of the dialysate and the meas-
urement at the sensor side.
Conclusion
The point and trend accuracy of the tested microdialy-
sis-based CGM device was moderate to good in patients 
who were stable with regard to their blood glucose levels. 
Trend accuracy was very good. The device had no down-
times, but 4 out of 16 external sensors and 2 out of 12 
CVCs had practical problems.
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